key: cord-1039642-bmuis2j2
authors: Kurihara, Yoko; Kiyasu, Yoshihiko; Akashi, Yusaku; Takeuchi, Yuto; Narahara, Kenji; Mori, Sunao; Takeshige, Tomonori; Notake, Shigeyuki; Ueda, Atsuo; Nakamura, Koji; Ishikawa, Hiroichi; Suzuki, Hiromichi
title: The evaluation of a novel digital immunochromatographic assay with silver amplification to detect SARS-CoV-2
date: 2021-07-13
journal: J Infect Chemother
DOI: 10.1016/j.jiac.2021.07.006
sha: 74cc5b356c6db1a224b59d8f72146209a094cea7
doc_id: 1039642
cord_uid: bmuis2j2

Introduction Rapid antigen tests are convenient for diagnosing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); however, they have lower sensitivities than nucleic acid amplification tests. In this study, we evaluated the diagnostic performance of Quick Chaser® Auto SARS-CoV-2, a novel digital immunochromatographic assay that is expected to have higher sensitivity than conventional antigen tests. Methods A prospective observational study was conducted between February 8 and March 24, 2021. We simultaneously obtained two nasopharyngeal samples, one for evaluation with the QuickChaser® Auto SARS-CoV-2 antigen test and the other for assessment with reverse transcription PCR (RT-PCR), considered the gold-standard reference test. The limit of detection (LOD) of the new antigen test was compared with those of four other commercially available rapid antigen tests. Results A total of 1401 samples were analyzed. SARS-CoV-2 was detected by reference RT-PCR in 83 (5.9%) samples, of which 36 (43.4%) were collected from symptomatic patients. The sensitivity, specificity, positive predictive value, and negative predictive value were 74.7% (95% confidence interval (CI): 64.0–83.6%), 99.8% (95% CI: 99.5–100%), 96.9% (95% CI: 89.2–99.6%), and 98.4% (95% CI: 97.6–99.0%), respectively. When limited to samples with a cycle threshold (Ct) <30 or those from symptomatic patients, the sensitivity increased to 98.3% and 88.9%, respectively. The QuickChaser® Auto SARS-CoV-2 detected 34–120 copies/test, which indicated greater sensitivity than the other rapid antigen tests. Conclusions QuickChaser® Auto SARS-CoV-2 showed sufficient sensitivity and specificity in clinical samples of symptomatic patients. The sensitivity was comparable to RT-PCR in samples with Ct<30.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic and continues to place an immense burden on healthcare systems [1] despite the introduction of effective vaccines [2] . Since rapid and accurate testing is a critical element in containing viral transmission [3] , the development of reliable pointof-care testing is necessary.

Nucleic acid amplification tests (NAATs) are the gold standard for diagnosing coronavirus disease 2019 (COVID-19) because of their high diagnostic performance [4] . However, several limitations have reduced their test capacity and clinical utility, including long processing times and the need for expensive equipment and skilled staff [3] . By contrast, antigen tests are convenient and have moderate sensitivities and high specificities [4] . These tests have made it possible to diagnose COVID-19 in lowresource settings [5] , despite the possibility of missing a certain proportion of infected patients [6] . Therefore, increasing sensitivity should enhance the clinical utility of antigen tests.

Quick Chaser ® Auto SARS-CoV-2 (Mizuho Medy, Saga, Japan) is a new antigen test based on the silver amplification method. This test uses the same reagent as FUJI DRY-CHEM IMMUNO AG Cartridge COVID-19 Ag (Fujifilm, Tokyo, Japan), and is tailored for digital immuno-chromatographic assays. The test provides results in 15 minutes when used with the QuickChaser Immuno Reader II dedicated reader (Mizuho Medy). Both the silver amplification method and digital immunochromatographic assays were reported to increase the sensitivity of antigen tests for the J o u r n a l P r e -p r o o f influenza virus [7] . Although Quick Chaser ® Auto SARS-CoV-2 is expected to have higher sensitivity than conventional antigen tests, its diagnostic performance for detecting SARS-CoV-2 has not been evaluated in clinical samples.

In this study, we evaluated the diagnostic performance of Quick Chaser ® Auto SARS-CoV-2 and QuickChaser Immuno Reader II with nasopharyngeal specimens, and performed comparisons with the reverse transcription PCR (RT-PCR) method.

This study was carried out as an extension of our previous research [8] and followed a similar protocol. The investigation was performed between February 8 and March 24, 2021, at Tsukuba Medical Center Hospital (TMCH), a tertiary hospital in Ibaraki Prefecture, Japan. Nasopharyngeal samples and clinical information were gathered from individuals who had possibly contracted SARS-CoV-2. The enrolled patients were referred from 67 nearby clinics and a local public health center, and by healthcare workers at TMCH. All patients provided informed consent to participate in the study, which was approved by the ethics committee of TMCH (approval number: 2020-071).

Two nasopharyngeal samples were obtained from each patient for further testing: one with a sponge swab™ (NIPRO, Osaka, Japan) for antigen testing, and the J o u r n a l P r e -p r o o f other with FLOQSwab™ (Copan Italia S.p.A., Brescia, Italy) for the RT-PCR assay.

After sample collection, antigen testing was performed immediately using the QuickChaser ® Auto SARS-CoV-2 and QuickChaser Immuno Reader II. FLOQSwab samples were diluted in 3 mL of Universal Transport Medium™ (UTM™) (Copan Italia) for in-house RT-PCR and reference RT-PCR.

magLEAD 6gC (Precision System Science, Chiba, Japan) was used for extraction and purification of RNA from UTM™ samples. GENECUBE and GENECUBE ® HQ SARS-CoV-2 were used for in-house RT-PCR [9] . The purified samples were then transferred to Mizuho Medy for reference real-time RT-PCR. The N2 primer/probe set (Nihon Gene Research Laboratories, Miyagi, Japan) was employed for reference RT-PCR as suggested by the "Manual for the Detection of Pathogen 2019-nCoV Ver. 2.9.1" issued by the National Institute of Infectious Diseases of Japan [10] .

The RT-PCR assays were performed on a Thermal Cycler Dice III (Takara Bio, Kusatsu, Japan) using One Step PrimeScript™ III RT-qPCR Mix (Takara Bio) with the following cycling conditions: reverse transcription at 52 °C for 5 min and at 95 °C for 19 Ag Rapid Test Device, 1,098-1,924 copies/test; and SARS-CoV-2 Rapid Antigen Test, 549-1,924 copies/test. Sensitivity, specificity, PPV, and NPV of QuickChaser ® Auto SARS-CoV-2

The clinical performance of QuickChaser ® Auto SARS-CoV-2 is summarized in Tables 2 and 3 . Sixty-two of the 83 samples that were positive by reference RT-PCR were also positive by the antigen test. The sensitivity, specificity, PPV, and NPV were 74.7% (95% CI: 64.0-83.6%), 99.8% (95% CI: 99.5-100%), 96.9% (95% CI: 89.2-99.6%), and 98.4% (95% CI: 97.6-99.0%), respectively ( Table 2 ).

In samples from symptomatic patients, 32 of 36 reference RT-PCR-positive samples were also positive by antigen testing (Table 3a) . The sensitivity, specificity, PPV, and NPV were 88.9% (95% CI: 73.9-96.9%), 100% (95% CI: 99.3-100%), 100% (95% CI: 84.2-100%), and 99.5% (95% CI: 98.8-99.9%), respectively.

In samples from asymptomatic individuals, 30 of 47 reference RT-PCR-positive samples were positive by antigen testing (Table 3b ). The sensitivity, specificity, PPV, and NPV were 63.8% (95% CI: 48.5-77.3%), 99.6% (95% CI: 98.5-100%), 93.8% (95% CI: 79.2-99.2%), and 96.7% (95% CI: 94.7-98.0%), respectively.

The sensitivities of the antigen test stratified by Ct value are shown in Table 4 . 

In this prospective study, Quick Chaser ® Auto SARS-CoV-2 using nasopharyngeal specimens demonstrated a sensitivity of 74.7% and a specificity of 99.8%. In patients with Ct values <30, the sensitivity was almost identical to RT-PCR.

Furthermore, Quick Chaser ® Auto SARS-CoV-2 had a lower LOD than other antigen tests currently approved in Japan.

Several antigen tests have been developed, with generally high specificity and variable sensitivity [5] . While Quick Chaser ® Auto SARS-CoV-2 had the lowest LOD in this study, QuickNavi [8] and Panbio [11] had comparable sensitivities. The diagnostic performance of antigen tests may differ between experimental (UTM™) and clinical samples [12] . Also, the current LOD evaluation was performed by three J o u r n a l P r e -p r o o f researchers without a blinded manner, and therefore observer bias was a significant concern. Additionally, antigen concentrate dilution, which is the method recommended in package inserts for testing UTM samples using the Espline SARS-CoV-2 Assay, was not used in this study. Therefore, direct comparison using clinical samples should be conducted to evaluate the real-life performance of each test. Viral load influences overall sensitivity, as shown by the fact that the sensitivity of antigen tests generally plummets in samples with Ct >30 [8, 13] . Samples with Ct >30 comprised 30.1% (25/83) of our study population, which may have decreased the overall sensitivity of Quick Chaser ® Auto SARS-CoV-2. Another factor that may influence sensitivity is the swab type used. Quick Chaser ® Auto SARS-CoV-2 includes sponge swabs, although flocked-type swabs can collect samples more efficiently [14] .

Despite the aforementioned challenges, this antigen test successfully detected SARS-CoV-2 in all but one of the samples with Ct <30. The remaining case was a false negative, and considering that re-examination with the UTM™ sample showed a positive result, the original finding may have been caused by a low viral concentration due to a flawed sample collection technique. The good performance of this test indicates that it can accurately identify contagious patients, given that those with Ct values <30 are considered to be highly infectious [15] .

We observed false positives in only two samples, and the specificity of Quick Chaser ® Auto SARS-CoV-2 was over 99%. False positives should be avoided as they lead to unnecessary further testing or quarantine measures [16] ; thus, the specificity is recommended to be over 97% [5] . Positive results should be cautiously interpreted, To maximize its sensitivity, Quick Chaser ® Auto SARS-CoV-2 uses two methods: silver amplification and digital interpretation of the results. Similar to many antigen tests [5] , Quick Chaser ® Auto SARS-CoV-2 implements sandwich methods using labeled antibodies and capture antibodies. Antibodies labeled with gold colloid attach to specific antigens in a sample. The labeled antigens are then sandwiched by capture antibodies, which indicate the positive bands. The silver amplification method generates large silver particles using the gold colloid as a catalyst, and thus enhances the visibility of the labeled antibody complex [7] . A previous study showed that among antigen tests for the influenza virus, those that used this method had higher sensitivity than those that did not (type A, 91.2% vs. 86.8%, respectively; type B, 94.4% vs. 81.2%, respectively), without compromising specificity [17] . Similarly, digital scans of the test reagents can improve the accuracy of antigen detection. Digital scans also increase the objectivity of test result interpretation by removing the necessity for visual inspection. A systematic review suggested that digital immunoassays increased sensitivities by 25.5% and 23.5% for influenza A and B, respectively [18] . Although digital immunoassays require special equipment, the additional cost is much cheaper than that of NAATs, and is compensated for by the increase in sensitivity [18] .

There are several limitations regarding this study. First, reference real-time RT-PCR used frozen samples. While samples were stored at −80 °C, their viral load may J o u r n a l P r e -p r o o f have decreased during storage process. Second, we did not investigate whether mutations in SARS-COV-2 affected the diagnostic performance. Third, we did not evaluate saliva or anterior nasal cavity samples. Saliva collection and anterior nasal swabs cause less pain and coughing than nasopharyngeal swabs [19] . Future studies should compare the diagnostic performance of samples obtained using each of these methods.

In conclusion, Quick Chaser ® Auto SARS-CoV-2 showed satisfactory diagnostic performance of symptomatic patients. The sensitivity was especially high in samples of Ct <30, indicating that the test can accurately detect highly infectious patients. J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f 

World Health Organization. Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update

SARS-CoV-2 Vaccines

Challenges in laboratory diagnosis of the novel coronavirus SARS-CoV-2

World Health Organization. Diagnostic testing for SARS-CoV-2: interim guidance

Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO

Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection

Development of a highly sensitive immunochromatographic detection kit for H5 influenza virus hemagglutinin using silver amplification

The evaluation of a newly developed antigen test (QuickNavi TM -COVID19 Ag) for SARS-CoV-2: A prospective observational study in Japan

A Prospective Evaluation of the Analytical Performance of GENECUBE ® HQ SARS-CoV-2 and GENECUBE ® FLU A/B

Development of genetic diagnostic methods for detection for novel coronavirus

Evaluation of a rapid antigen test (Panbio TM COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patients

Real-life validation of the Panbio TM COVID-19 antigen rapid test (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infection

Evaluation of the panbio COVID-19 rapid antigen detection test device for the screening of patients with COVID-19

Comparison of flocked and rayon swabs for collection of respiratory epithelial cells from uninfected volunteers and symptomatic patients

Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples

Another false-positive problem for a SARS-CoV-2 antigen test in Japan

Clinical evaluation of highly sensitive silver amplification immunochromatography systems for rapid diagnosis of influenza

Diagnostic Accuracy of Novel and Traditional Rapid Tests for Influenza Infection Compared With Reverse Transcriptase Polymerase Chain Reaction: A Systematic Review and Meta-analysis

Diagnostic performance and characteristics of anterior nasal collection for the SARS-CoV-2 antigen test: a prospective study

We thank the staff in the Department of Clinical Laboratory of Tsukuba MedicalCenter Hospital for their intensive support of this study. We thank all of the medical institutions for providing their patients' clinical information.